|
Primary Response Analysisa
|
|---|
| |
AboBoNT-A (N = 253)
|
OnaBoNT-A (N = 103)
|
All Patients (N = 356)
|
|---|
|
Unadjusted
|
|
Mean Total Cost (€)
|
310.31
|
355.87
|
323.49
|
|
Mean Response Rate
|
0.32
|
0.22
|
0.29
|
|
Mean Cost-Per-Responder
|
969.23
|
1593.69
|
1107.33
|
|
Adjustedb
|
|
Mean Total Cost (€)
|
314.18
|
346.35
| |
|
Mean Response Rate
|
0.32
|
0.23
| |
|
Mean Cost-Per-Responder
|
986.35
|
1523.77
| |
|
Alternative Response Analysisc
|
| |
AboBoNT-A (N = 251)
|
OnaBoNT-A (N = 103)
|
All Patients (N = 354)
|
|
Unadjusted
|
|
Mean Total Cost (€)
|
310.30
|
355.87
|
323.56
|
|
Mean Response Rate
|
0.34
|
0.19
|
0.30
|
|
Mean Cost-Per-Responder
|
916.30
|
1832.75
|
1090.86
|
|
Adjustedb
|
|
Mean Total Cost (€)
|
314.30
|
346.12
| |
|
Mean Response Rate
|
0.34
|
0.20
| |
|
Mean Cost-Per-Responder
|
931.45
|
1755.83
| |
- aResponse is defined as: ≥25% improvement in TWSTRS severity scores at visit 2, at least a 12 week interval between injection and subject report of treatment waning, no report of related severed adverse events a visit 2 or visit 3, and a Clinical Global Improvement (CGI) score equal to either + 2 or + 3 at visit 2
- bAdjusted for age, sex, prior treatment with BoNT-A, and use of EMG at baseline
- aboBoNT-A abobotulinumtoxinA; onaBoNT-A onabotulinumtoxinA
- cResponse is defined as: ≥25% improvement in TWSTRS severity scores at visit 3, and no report of a severe adverse event related to BoNT-A injection at visit 3
